FDA safety update
Avacopan: read the liver warning and regulatory status separately
A liver-monitoring plan and a regulatory headline answer different questions. FDA reported serious avacopan liver injury in March 2026, then proposed withdrawal of Tavneos approval in April. A pharmacy case needs the safety response without turning a proposal into a completed market removal.
Sources checked October 8, 2026. Independent educational content, not NABP exam questions or individual treatment advice.
Use the full liver panel and the stated schedule
FDA advises liver panel testing every two weeks during the first month, monthly during the next five months, then as clinically indicated. A note that says only "check liver tests sometime" loses the early interval, while an ALT-only check can miss a cholestatic pattern.
The communication includes drug-induced liver injury, fatal outcomes and vanishing bile duct syndrome. The latter involves progressive bile-duct loss and can cause persistent damage. Its mention is a reason to recognize serious cholestatic symptoms, not to diagnose the syndrome from a single itchy patient.
Separate symptoms from a routine appointment
FDA lists unusual fatigue, nausea or vomiting, itching, pale stools, jaundice, dark urine, abdominal swelling and right-upper-abdominal pain as possible liver-injury symptoms. Patients should contact their health care professional immediately rather than wait for scheduled monitoring.
For clinicians, the communication advises promptly discontinuing Tavneos and evaluating when ALT or AST exceeds three times the upper limit of normal, ALP exceeds twice that limit, or symptomatic cholestasis appears. Persistent abnormalities or symptoms need hepatology review. A simplified lesson does not replace that clinician-led response.
Do not turn reported cases into an incidence
FDA identified 76 cases with reasonable evidence of a causal association, including serious and fatal outcomes. This postmarketing series provides a safety signal, not the proportion of every treated person who will be injured. There is no exposed-user denominator for a reliable individual risk percentage.
Preserve both the signal and its limits. A small number of US reports does not prove absence of risk in US patients, and the communication does not say that symptoms must appear on one particular treatment day. Current symptoms matter even when a prior panel was reassuring.
Name the regulatory step accurately
The April 27 FDA page describes CDER proposing withdrawal because of effectiveness and application-integrity concerns, as well as safety concerns. It says the medicine remains on the market until applicant removal or a Commissioner decision. Do not rewrite "proposes" as "has withdrawn."
The manufacturer update also describes continued availability, but its benefit-risk position is the manufacturer's position, not an independent resolution of FDA's concerns. Check the current official status for a real dispensing decision and discuss continuation or alternatives with the treating team. The regulatory dispute does not suspend symptom assessment.
A worked case
A patient six weeks into avacopan has new itching, dark urine and yellow eyes. The next monthly panel is two weeks away. They also read that FDA proposed withdrawing approval. What should the pharmacy response prioritize?
- Treat the current symptoms as possible liver injury requiring immediate clinical contact.
- Communicate the treatment timing, symptoms and monitoring history to the treating team; do not wait for the booked panel.
- Explain the proposal accurately without claiming a completed withdrawal or independently choosing replacement therapy.
Answer: Prompt liver-injury assessment comes first; the proposal and treatment decision remain separate facts.
Try it before reading the answer
Write the key fact, decision and safety check first. These are original practice exercises, not recalled exam items.
1. Does a withdrawal proposal prove the drug has already left the market?
No. The cited FDA page describes a proposal and the process for a final decision.
2. Can a normal earlier panel rule out injury with new jaundice?
No. New symptoms require immediate assessment.
3. Can the 76 cases be stated as a patient-level percentage risk?
No. The report series lacks an exposed-user denominator.
Continue learning
Put the topic into a study planSources and scope
Source dates and limits matter. Follow the current official source for clinical or regulatory decisions. Examples are simplified teaching cases, not prescribing, diagnostic or compounding instructions. Check the full current guidance and individual clinical context.